Preventative cardiovascular MD gets "Freedom to Discover"
A specialist in preventative cariovascular medicine at the University of Pennsylvania School of Medicine, USA, has been selected to direct a "Freedom to Discover" unrestricted biomedical research grant, which was awarded to the university by New York, USA-based drugmaker Bristol-Myers Squibb. Daniel Rader is one of two scientists in the cardiovascular field to benefit from such an award in 2006, a total of $6.0 million being distributed by the company this year. He is best known for his work on high-density lipoprotein cholesterol.
The Freedom to Discover Award includes $100,000 per year for five years. Dr Rader said: "this research money will enable us to try new approaches to targeting HDL for therapeutic purposes, a key step in our goal of preventing and reversing heart disease."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze